Study: Why Patients Stop GLP-1 Medications

Last reviewed: June 11, 2026

Last updated: June 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 medications like semaglutide have transformed weight loss treatment, but research indicates that up to 40% of patients stop taking them within the first year. The reasons behind this dropout rate reveal important gaps in how these medications are prescribed and supported—and how precision medicine may close them.

GLP-1 Discontinuation Rates: What the Research Shows

Clinical studies tracking real-world GLP-1 use reveal that medication adherence drops significantly after month six. Patients cite multiple overlapping reasons for stopping, rather than a single barrier. The most common factor is gastrointestinal side effects—nausea, constipation, and appetite suppression that feels excessive rather than therapeutic. When side effects persist beyond the initial adjustment period, many patients conclude the medication isn't right for them and stop without exploring alternatives.

Cost is the second major discontinuation driver, even among insured patients. Out-of-pocket expenses for branded GLP-1 drugs can exceed $900 per month, pushing some patients to ration doses or skip weeks. Uninsured patients face even steeper barriers, with retail prices often exceeding $1,200 monthly. This financial friction becomes critical at the three-month mark, when initial motivation plateaus and patients reassess whether the investment matches their results.

Side Effects and the Personalization Gap in GLP-1 Therapy

Not all GLP-1 side effects indicate a medication failure. Many stem from dose escalation that's too rapid or a mismatch between the patient's genetic sensitivity to GLP-1 receptor signaling and the standard protocol. A patient with high genetic sensitivity to GLP-1R activation may experience intolerable nausea on doses that work well for others. Without genetic insight, providers typically respond by stopping the medication rather than adjusting the approach—a missed opportunity for personalized success.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Cost and Access Barriers Driving Early Treatment Dropout

Financial stress is a silent killer of GLP-1 adherence. Patients who begin treatment with high hopes often face sticker shock at their first refill, especially if they pay out-of-pocket or have high deductible plans. Insurance denial and prior authorization delays add months to treatment setup, eroding initial momentum. By the time a patient finally receives their first dose, motivation may have faded, or they've already pivoted to cheaper alternatives with weaker evidence.

PlexusDx removes cost as a discontinuation barrier by offering compounded semaglutide injection at $189/mo month-to-month, or from $149/mo on the 6-month plan—a flat rate that does not change as dose increases. This pricing model means patients can titrate to their optimal therapeutic dose without financial penalty. HSA and FSA eligibility further reduces out-of-pocket burden, and the absence of membership fees or insurance requirements eliminates prior authorization delays. Transparent, predictable pricing supports long-term adherence.

How Precision Medicine Reduces GLP-1 Treatment Abandonment

Patients who discontinue GLP-1 therapy often don't need to stop—they need to switch. A patient experiencing severe nausea on semaglutide injection may tolerate oral semaglutide or tirzepatide injection with a slower titration schedule. Another patient may benefit from the dual-compound approach of GLP-Squared, which combines semaglutide and tirzepatide in one formulation for synergistic appetite suppression and metabolic benefit. The key is matching the right medication, formulation, and dose to the individual's genetics, tolerance, and lifestyle.

PlexusDx providers use genetic testing, medical history, and real-time symptom tracking to build a personalized GLP-1 plan that evolves with the patient. If side effects emerge, the clinical team can adjust dose, switch formulations, or add supportive care—rather than abandoning treatment altogether. This proactive personalization reduces the likelihood that a patient experiences GLP-1 as a one-size-fits-all failure and instead perceives it as a tool calibrated to their body.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Why do so many patients stop taking GLP-1 medications?

Research shows the top reasons are persistent side effects (nausea, constipation), high out-of-pocket costs, and lack of personalization to individual genetics and tolerance. When patients feel unsupported or financially burdened, they discontinue rather than explore alternatives. PlexusDx addresses all three factors: genetic testing identifies optimal formulations, flat pricing removes cost escalation, and clinical support adjusts treatment as needed.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to GLP-1 medications or any specific medication. It analyzes pathway-level variants (GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

How does PlexusDx pricing support long-term adherence?

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) and maintains that flat price as your dose increases—your dose may go up, but your price won't. This predictable, low-cost model removes financial barriers at refill time, a critical dropout point. All medications are HSA/FSA eligible and available in all 50 states without insurance or membership fees.

Can I switch GLP-1 medications if my current one isn't working?

Absolutely. If semaglutide causes intolerable side effects, switching to oral semaglutide, tirzepatide injection, oral tirzepatide, or GLP-Squared may be more tolerable. PlexusDx providers can help you transition between formulations and compounds while adjusting dose and titration speed to match your genetics and tolerance profile.

What makes PlexusDx medications different from branded GLP-1 drugs?

PlexusDx compounds all medications in licensed 503A compounding pharmacies, ensuring pharmaceutical-grade quality at a fraction of branded prices. More importantly, PlexusDx combines affordable access with genetic personalization: the Precision Peptide Genetic Test maps 14 metabolic pathways and 49 peptides, helping providers select the formulation and dose most likely to work for your unique biology. This personalized approach reduces side effects and discontinuation.

Related Reading

• Glp 1 Medications
• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• Can A Dna Test Reveal If I Will Benefit From Glp 1 Medications
• Maximus Glp 1

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.